Results 11 to 20 of about 1,116,502 (236)
ClinicoEconomics and Outcomes Research, 2015 Habip Gedik Department of Infectious Diseases and Clinical Microbiology, Ministry of Health Okmeydani Training and Research Hospital, Istanbul, Turkey Objective: The aim of this study is to analyze the expenditures related to the use of antifungal drugs
Gedik H
doaj +1 more source
Genetic and structural validation of Aspergillus fumigatus UDP-N-acetylglucosamine pyrophosphorylase as a potential antifungal target [PDF]
, 2013 The sugar nucleotide UDP-N-acetylglucosamine (UDP-GlcNAc) is an essential metabolite in both prokaryotes and eukaryotes. In fungi, it is the precursor for the synthesis of chitin, an essential component of the fungal cell wall.
Raimi, Olawale G. +7 more
core +5 more sources
Antifungal and Immunomodulatory Ingredients from Traditional Chinese Medicine
Antibiotics, 2022 Fungal infections have become a growing public health challenge due to the clinical transmission of pathogenic fungi. The currently available antifungal drugs leave very limited choices for clinical physicians to deal with such situation, not to mention ...
Hua Zhong, Lei Han, Ren-Yi Lu, Yan Wang
doaj +1 more source
Frontiers in Cellular and Infection Microbiology, 2022 Fungal infection is a serious global health issue, causing approximately 1.5 million mortalities annually. However, clinically available anti-fungal drugs are limited, especially for multidrug-resistant fungal infections.
Jiaying Lin +7 more
doaj +1 more source
Reshaping Echinocandin Antifungal Drugs to Circumvent Glucan Synthase Point Mutation-Mediated Resistance [PDF]
, 2023 Echinocandins are important antifungal drugs that inhibit the activity of the membrane-bound glucan synthase complex, which is responsible for the synthesis of the fungal cell wall β-(1,3)-glucan.
Moriah, Jospe-Kaufman +3 more
core +2 more sources
Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome® or Fungizone™ [PDF]
, 2011 Background: Despite advances in the treatment, the morbidity and mortality rate associated with invasive aspergillosis remains unacceptably high (70–90%) in immunocompromised patients.
M N V Ravi Kumar +20 more
core +5 more sources
Antifungal Polymeric Materials and Nanocomposites
Frontiers in Bioengineering and Biotechnology, 2021 Rising global populations due to medicinal advancements increases the patient population susceptible to superficial and severe fungal infections. Fungi often implicated in these diseases includes the dermatophytes (Microsporum spp., Epidermophtyon spp ...
Winnie Ntow-Boahene +2 more
doaj +1 more source
Treatment of atopic dermatitis using topical antifungal drugs: A meta‐analysis
Dermatologic Therapy, 2022 Several studies have focused on treating atopic dermatitis (AD) using topical antifungal drugs. However, their findings are inconsistent. This meta‐analysis of randomized controlled trials (RCTs) aimed to evaluate the safety and efficacy of topical ...
Dan He +5 more
doaj +1 more source
Marine Drugs, 2019 The mangrove ecosystem is a rich resource for the discovery of actinomycetes with potential applications in pharmaceutical science. Besides the genus Streptomyces, Micromonospora is also a source of new bioactive agents.
Rui-Jun Wang +8 more
doaj +1 more source
Fungal infections: Pathogenesis, antifungals and alternate treatment approaches
Current Research in Microbial Sciences, 2022 Increasing incidence of fungal infections of recent times requires immediate intervention. Fungal infections are seldom construed at initial stages that intensify the severity of infections and complicate the treatment procedures. Fungal pathogens employ
G.Kiran Kumar Reddy +2 more
doaj +1 more source